The Blood and Marrow Transplant Clinical Trials Network - Core Clinical Centers (UG1 Clinical Trial Optional)

Background
The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) is a clinical trials network sponsored by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI). The network aims to provide the infrastructure for multi-site collaborative clinical trials evaluating hematopoietic cell transplantation (HCT) and adoptive cell therapy approaches to cure blood diseases. The BMT CTN has conducted more than 50 Phase II and Phase III trials to address key issues for the field, including donor availability, treating or preventing graft versus host disease (GVHD) or infections, disease control, treatment-related toxicity, cost-effectiveness, and quality of life.

Grant Details
The purpose of this initiative is to advance hematopoietic cell transplantation (HCT) for all patients, particularly those with rare and difficult-to-treat non-malignant blood diseases and hematological malignancies. The initiative aims to support a clinical trials network to evaluate novel cell therapy (CT) and HCT approaches. It will fund a Data Coordinating Center (DCC) and core clinical sites, as well as a limited number of trials. Additional studies and trials will be funded through collaborations with R01-funded grantees, industry, and foundations. The program will support these activities over a seven-year period.

Eligibility Requirements
Eligible applicants include higher education institutions, nonprofits, for-profit organizations, state and local governments, federally recognized Indian/Native American tribal governments, federal agencies, U.S. territories or possessions, public housing authorities/Indian housing authorities, faith-based or community-based organizations, regional organizations, independent school districts, and Native American tribal organizations. Foreign institutions are not eligible to apply.

Period of Performance
The program has a maximum project period of 7 years.

Grant Value
The National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI) intend to commit total costs of up to $4.32M in Fiscal Year 2024 to fund approximately 18 awards. Application budgets may request up to $150,000 direct costs per year in FY24 through FY30.